Pfizer: Kidney Neoplasms trials

The registry lists 21 Kidney Neoplasms studies with Pfizer as lead sponsor. 1 are open to participants now and 15 have results posted.

Phase 1 4Phase 2 5Phase 3 6No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingNCT07227415Phase 1/2
• A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.CompletedNCT05363072Results posted
• Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National RegistriesCompletedNCT04669366Results posted
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedNCT02684006Phase 3Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)CompletedNCT02493751Phase 1Results posted
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedNCT02315066Phase 1Results posted
• Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell CancerCompletedNCT00920816Phase 3Results posted
• Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With SutentCompletedNCT00836745Results posted
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney CancerCompletedNCT00835978Phase 2Results posted
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell CancerCompletedNCT00678392Phase 3Results posted
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsCompletedNCT00631371Phase 3Results posted
• SUTENT® In The First Line Treatment Of Renal Cell CarcinomaCompletedNCT00460798Results posted
• A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell CancerCompletedNCT00375674Phase 3Results posted
• Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell CancerCompletedNCT00282048Phase 2Results posted
• Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell CarcinomaCompletedNCT00076011Phase 2Results posted
• Study Evaluating Interferon And CCI-779 In Advanced Renal Cell CarcinomaCompletedNCT00065468Phase 3Results posted
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).CompletedNCT05858749
• A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerWithdrawnNCT04889495
• Study In Patients With Kidney Cancer Treated With SutentCompletedNCT00873210
• Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney CancerCompletedNCT00054886Phase 2